公开(公告)号：US10472386B2

公开(公告)日：2019-11-12

申请号：US15896400

申请日：2018-02-14

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Yat Sun Or ,  Ruichao Shen ,  Xuechao Xing ,  Jiang Long ,  Peng Dai ,  Brett Granger ,  Jing He

IPC: C07J41/00 ,  C07J9/00 ,  C07J43/00 ,  C07J51/00

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, prodrugs and esters thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US10457703B2

公开(公告)日：2019-10-29

申请号：US15085800

申请日：2016-03-30

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Yat Sun Or ,  Ruichao Shen ,  Xuechao Xing ,  Jiang Long ,  Peng Dai ,  Brett Granger ,  Jing He

IPC: C07J43/00 ,  C07J41/00 ,  C07J9/00 ,  C07J51/00

Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US20170334893A1

公开(公告)日：2017-11-23

申请号：US15597417

申请日：2017-05-17

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Jun Ma ,  Bin Wang ,  Yong He ,  Xuechao Xing ,  Ruichao Shen ,  Brett Granger ,  Jing He ,  Jiang Long ,  Guoqiang Wang

IPC: C07D413/12 ,  C07D261/08

CPC classification number: C07D413/12 ,  A61K31/42 ,  C07D261/08

Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

公开(公告)号：US20170304270A1

公开(公告)日：2017-10-26

申请号：US15497268

申请日：2017-04-26

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Brett Granger ,  Ruichao Shen ,  Xuechao Xing ,  Bin Wang ,  Jun Ma ,  Jing He ,  Jiang Long ,  Yong He ,  Guoqiang Wang

IPC: A61K31/42 ,  C07D261/06 ,  C07D413/04 ,  C07D413/12

CPC classification number: A61K31/42 ,  C07D261/06 ,  C07D261/08 ,  C07D413/04 ,  C07D413/12

Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.

公开(公告)号：US11420976B2

公开(公告)日：2022-08-23

申请号：US17155159

申请日：2021-01-22

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yong He ,  Xuechao Xing ,  Guoqiang Wang ,  Ruichao Shen ,  Brett Granger ,  Jiang Long ,  Yat Sun Or

IPC: C07D491/048 ,  A61K45/06

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV) or HMPV. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV or HMPV infection. The invention also relates to methods of treating an RSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20200308193A1

公开(公告)日：2020-10-01

申请号：US16828243

申请日：2020-03-24

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Brett Granger ,  Yong He ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D519/00 ,  C07D487/04

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US20190337935A1

公开(公告)日：2019-11-07

申请号：US16400498

申请日：2019-05-01

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Brett Granger ,  Guoqiang Wang ,  Ruichao Shen ,  Jing He ,  Yat Sun Or

IPC: C07D417/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis disease (NASH).

公开(公告)号：US10450301B2

公开(公告)日：2019-10-22

申请号：US15988806

申请日：2018-05-24

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Brett Granger ,  Guoqiang Wang ,  Ruichao Shen ,  Jing He ,  Yong He ,  Xuechao Xing ,  Jun Ma ,  Jiang Long ,  Bin Wang ,  Yat Sun Or

IPC: A61K31/4375 ,  A61K31/4725 ,  C07D401/14 ,  C07D471/04 ,  C07D471/08 ,  C07D417/14 ,  C07D451/02 ,  C07D451/06

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US20180362501A1

公开(公告)日：2018-12-20

申请号：US15988763

申请日：2018-05-24

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Brett Granger ,  Ruichao Shen ,  Yong He ,  Xuechao Xing ,  Jun Ma ,  Jiang Long ,  Jing He ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D491/107 ,  C07D498/08 ,  C07D401/04

CPC classification number: C07D401/14 ,  C07D401/04 ,  C07D491/107 ,  C07D498/08

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US10138228B2

公开(公告)日：2018-11-27

申请号：US15597423

申请日：2017-05-17

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Yong He ,  Ruichao Shen ,  Xuechao Xing ,  Brett Granger ,  Bin Wang ,  Jun Ma ,  Jing He ,  Jiang Long ,  Guoqiang Wang

IPC: A61K31/42 ,  C07D413/12

Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated as FXR modulators. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR, and methods for their preparation and use.